Literature DB >> 2785413

Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma.

M Kawano1, I Yamamoto, K Iwato, H Tanaka, H Asaoku, O Tanabe, H Ishikawa, M Nobuyoshi, Y Ohmoto, Y Hirai.   

Abstract

Human myeloma cells were purified from bone marrow aspirates from four patients having advanced myeloma, including one with common acute lymphoblastic leukemia antigen-positive myeloma. All of these myelomas had marked bone lytic lesions. From the culture supernatants of these purified myeloma cells, bone-resorbing activities were significantly revealed by 45Ca-release bone resorption assay, and IL-1 activities were also detected by IL-1 bioassay (mouse thymocyte comitogenic assay). Sandwich enzyme immunoassay for IL-1 alpha or IL-1 beta revealed that IL-1 beta was responsible for IL-1 activity of these culture supernatants. Furthermore, the bone resorbing activities of these culture supernatants were completely neutralized by pretreatment of anti-IL-1 beta, but not anti-IL-1 alpha antibody. By Northern blot analysis, IL-1 beta mRNA was identified from these myeloma cells. Therefore, it is concluded that myeloma cells produce IL-1 beta, which acts as bone-resorbing activity in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785413

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells.

Authors:  T Sunyer; J Lewis; P Collin-Osdoby; P Osdoby
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

Review 3.  The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Authors:  E V McCloskey; J F Guest; J A Kanis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma.

Authors:  D Chappard; J F Rossi; R Bataille; C Alexandre
Journal:  Calcif Tissue Int       Date:  1991-01       Impact factor: 4.333

Review 5.  Hypercalcemia in malignancy.

Authors:  G J Strewler; R A Nissenson
Journal:  West J Med       Date:  1990-12

6.  Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro.

Authors:  R S Taichman; P V Hauschka
Journal:  Inflammation       Date:  1992-12       Impact factor: 4.092

7.  Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop.

Authors:  R Burger; J Wendler; K Antoni; G Helm; J R Kalden; M Gramatzki
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

8.  The anti-inflammatory role of vitamin e in prevention of osteoporosis.

Authors:  A S Nazrun; M Norazlina; M Norliza; S Ima Nirwana
Journal:  Adv Pharmacol Sci       Date:  2011-11-17

Review 9.  Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.

Authors:  Sonia Vallet; Julia-Marie Filzmoser; Martin Pecherstorfer; Klaus Podar
Journal:  Pharmaceutics       Date:  2018-10-24       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.